Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes
Boehringer Ingelheim Pharmaceuticals and Eli Lilly (NYSE: LLY) today announced results of a 78-week phase III clinical trial of the investigational agent empagliflozin* as add-on to basal insulin in adults with type 2 diabetes (T2D). The study, presented at the American Diabetes Association 73rd Scientific Sessions®, showed that empagliflozin 10 mg or 25 mg, plus insulin, produced statistically significant reductions in HbA1c (average blood glucose) compared with insulin alone at the study's primary endpoint, week 18, as well as at week 78.1
Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.